The TOGETHER Study, published in Lancet, evaluated the role of fluvoxamine in the treatment of COVID-19. Is this a real GameChanger, or just another dud? Lay media has been picking up the study - listen to Geoff and Jake break down the article to help healthcare providers give evidence-based recommendations.
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
Redeem your CPE or CME credit here!
Need a membership?
References and resources: Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021 Oct 27:S2214-109X(21)00448-4. doi: 10.1016/S2214-109X(21)00448-4. Epub ahead of print. PMID: 34717820; PMCID: PMC8550952.
WSJ Opinion on Fluvoxamine
Continuing Education Information:
1. Describe the inclusion and exclusion criteria for the TOGETHER study
2. Discuss the role of Drug-Drug Interactions with fluvoxamine
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-394-H01-P
Initial release date: 11/15/21
Expiration date: 11/15/22
Dr. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here